3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
6
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Thoracic
2
CNS
2
Tumor-Agnostic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
65
Nivolumab
59
Ipilimumab
33
Cyclophosphamide
23
Specimen Handling
16
Magnetic Resonance Spectroscopy
15
Biopsy
15
relatlimab
13
fludarabine
13
cemiplimab
13
Opdualag
12
Blood Specimen Collection
11
binimetinib
10
aldesleukin
9
Radiosurgery
9
Interleukin-2
9
encorafenib
8
atezolizumab
7
Immunotherapy
7
tebentafusp
6
mogamulizumab
6
fludarabine phosphate
6
Temozolomide
6
Surgical Procedures, Operative
6
Paclitaxel
6
Immunoglobulin G
6
CTLA-4 Antigen
6
Aminolevulinic Acid
6
Radiotherapy
5
Disulfides
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colony-Stimulating Factors
×
Dermatologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled